FDA Grants Accelerated Approval to Etcamah for Breast Cancer
Silver Spring, Maryland, USA, September 4, 2026 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
AstraZeneca
Advertisement
AstraZeneca Wins U.S. Approval for ETCAMAH in Breast Cancer
Cambridge, UK — September 4, 2026 AstraZeneca announced that ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor has received...
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
Amgen and AstraZeneca Report Positive Phase 3 EoE Data
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
AstraZeneca Discontinues eVOLVE-Lung02 Phase 3 Trial
Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...
Advertisements
Henlius and Sandoz Expand Global Strategic Biosimilar Effort
Shanghai, China, August 17, 2026 Shanghai Henlius Biotech, Inc. and Sandoz have entered into a strategic collaboration to expand...
Daiichi Sankyo and AstraZeneca Report Enhertu Phase 3 Win
Tokyo, Japan — August 17, 2026 Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Lung04 Phase 3...
HUTCHMED and AstraZeneca Advance ORPATHYS-TAGRISSO Lung Cancer Combination
Hong Kong, Shanghai & Florham Park, N.J., Aug. 17, 2026 HUTCHMED (China) Limited announced positive high-level results from the...
SOPHiA GENETICS Partners with AstraZeneca on CDx
Boston, Massachusetts & Rolle, Switzerland, August 4, 2026 SOPHiA GENETICS has entered into a global multi-year collaboration with AstraZeneca...
CervoMed Secures UK ILAP Innovation Passport for Neflamapimod
BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...
Advertisement
